New YorkAnd January 5 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-phase pharmaceutical company focused on developing oral drug delivery platforms, today announced that the European Patent Office has granted the company a patent titled “Compositions containing protease inhibitors”. compositions, and methods of their production and use. The patent supports Oramed’s oral protein delivery platform technology that underlies its lead drug candidate ORMD-0801 now in pivotal Phase 3 studies and positioned to be the first oral insulin capsule on the market. The granted patent covers a unique method for the purification of protease-inhibiting raw materials which is a key component of the platform technology that protects therapeutic proteins in the GI tract.
Oramed CEO stated, “With this newly granted patent, we now have 88 patents granted and 35 more pending, reinforcing Oramed’s leading position in terms of intellectual property assets addressing oral delivery of therapeutic proteins currently available only by injection,” Naddaf Kidron.
About Oramid Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq / TASE: ORMP) is a leading platform technology company for oral delivery solutions for today’s parenteral drug delivery. Founded in 2006, with offices in United State And IsraelOramed has developed a new oral protein delivery (POD™) technology. Oramed is seeking to transform diabetes treatment with its lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase III studies and could be the first commercial oral insulin capsule to treat diabetes. Additionally, Oramed is developing an oral GLP-1 (glucagon-like peptide-1) analog capsule (ORMD-0901).
For more information, please visit www.oramed.com.
Forward-looking statements: This press release contains forward-looking statements. For example, we use forward-looking statements when we discuss the expected timing of preliminary results from Phase 3 studies or the potential for ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historical results of scientific research and clinical trials do not guarantee that conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based only on Oramed management’s current expectations, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties regarding progress, timing, cost, results of clinical trials and product development programs; Difficulties or delays in obtaining regulatory approval or patent protection for candidates for our products; competition from other pharmaceutical or biotech companies; Our ability to obtain additional funding is required to conduct research, development and marketing activities. In addition, the following factors, among others, could cause actual results to differ materially from those shown in the forward-looking statements: changes in technology and market requirements; delays or obstacles in starting our clinical trials; changes in legislation inability to develop and introduce new technologies, products and applications in a timely manner; the lack of validation of our technology as we progressed and the lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to developing our products; unexpected scientific difficulties that may develop with our process; The cost of the final product is greater than expected; loss of market share and price pressure resulting from competition; lab results that do not translate into equally good results in real environments; Our patents may not be enough; Finally, the products may harm the recipient, all of which could cause actual results or Oramed’s performance to differ materially from those contemplated by such forward-looking statements. Except as otherwise required by law, Oramed has no obligation to publicly disclose any revisions to these forward-looking statements to reflect events or circumstances after the date of this contract or to reflect the occurrence of unforeseen events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s submissions from time to time to the Securities and Exchange Commission.
Source: Oramed Pharmaceuticals Inc.